Department of Medicine 2-Grosshadern, University of Munich, Munich, Germany.
Copyright © 2015 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: KGP has received research support by Genzyme, Merck Sharp & Dohme, and Novartis and honoraria for presentations, advisory board activities or DMC acitivities by Aegerion, Amgen, Chiesi, Fresenius, Genzyme, Kaneka, Kowa, Merck Sharp & Dohme, Novartis, Regeneron, Roche, Sanofi.
Statin | OR | 95% CI |
---|---|---|
Atorvastatin | 1.14 | 0.89-1.46 |
Simvastatin | 1.11 | 0.97-1.26 |
Rosuvastatin | 1.18 | 1.04-1.33 |
Pravastatin | 1.03 | 0.90-1.19 |
Lovastatin | 0.98 | 0.70-1.38 |
Overall | 1.09 | 1.02-1.17 |
Adjusted OR | |
---|---|
Not affected | 1 |
All affected | 0.49 |
apoB mutation | 0.65 |
LDL-R mutation | 0.45 |
LDL-R defective | 0.49 |
LDL-R negative | 0.38 |
Condition | Observation | Underlying pathophysiology | Clinical relevance |
---|---|---|---|
Diabetic dyslipidemia | Elevated triglycerides Low HDL-C Small-sense LDL particles | Due to inflammation and excessive availability of energy-rich substrates (glucose and/or free fatty acids) increased production of triglyceride-rich lipoproteins (fasting and postprandial) | Very important link between diabetes and cardiovascular risk; primary goal: treat LDL-C to target |
Dyslipidemia affecting glucose metabolism | Elevated triglycerides may deteriorate glucose metabolism | Elevated triglycerides → FFA → inflammation → increased insulin resistance/impaired β-cell function | Improving lipid metabolism may help to improve diabetes control; diabetic patient may need less antidiabetic therapy once lipids are normalized |
Low-HDL-C may deteriorate glucose metabolism | Low-HDL → less anti-inflammatory activity and less reverse cholesterol transport → altered microenvironment? → increased insulin resistance/impaired β-cell function | ||
Statins and new onset diabetes | Statin therapy leads to slightly increased risk in new onset type 2 diabetes | Probably indirect effect Due to inhibition of HMG-CoA reductase? Due to changes of intracellular lipid concentrations? | Patients with risk factors for diabetes are particularly susceptible; check glucose in patients on statin therapy |
Familial hypercholesterolemia and diabetes | Patients have a decreased risk for diabetes (dose-dependent: the higher the LDL-C, the less the risk) | Due to changes of intracellular lipid concentrations? Due to increased HMG-CoA reductase activity? | Unknown Statin therapy does not increase risk for new onset diabetes in patients with familial hypercholesterolemia |
Statin | OR | 95% CI |
---|---|---|
Atorvastatin | 1.14 | 0.89-1.46 |
Simvastatin | 1.11 | 0.97-1.26 |
Rosuvastatin | 1.18 | 1.04-1.33 |
Pravastatin | 1.03 | 0.90-1.19 |
Lovastatin | 0.98 | 0.70-1.38 |
Overall | 1.09 | 1.02-1.17 |
Adjusted OR | |
---|---|
Not affected | 1 |
All affected | 0.49 |
apoB mutation | 0.65 |
LDL-R mutation | 0.45 |
LDL-R defective | 0.49 |
LDL-R negative | 0.38 |
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FFA, free fatty acid; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A.
OR, odds ratio; CI, confidence interval.
OR, odds ratio; apoB, apolipoprotein B; LDL-R, low density lipoprotein receptor.